Drug Safety

A Benefit-Risk Review of Systemic Haemostatic Agents: Part 2: In Excessive or Heavy Menstrual Bleeding
pp. 275-282(8)
Authors: Fraser, Ian S.; Porte, Robert J.; Kouides, Peter A.; Lukes, Andrea S.

Dysglycaemias and Fluoroquinolones
pp. 283-292(10)
Authors: Lewis, Roshan J.; Mohr, John F.

Propofol Infusion Syndrome: An Overview of a Perplexing Disease
pp. 293-303(11)
Authors: Fodale, Vincenzo; Enza La Monaca,

Adequacy of Patient Information on Adverse Effects: An Assessment of Patient Information Leaflets in the UK
pp. 305-312(8)
Authors: Carrigan, Neil; Raynor, D.K.; Knapp, Peter

Safety Profile of Esomeprazole: Results of a Prescription-Event Monitoring Study of 11 595 Patients in England
pp. 313-323(11)
Authors: Davies, Miranda; Wilton, Lynda V.; Shakir, Saad A.W.

Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease: A Retrospective Cohort Study
pp. 325-334(10)
Authors: Avins, Andrew L.; Manos, Michele M.; Ackerson, Lynn; Zhao, Wei; Murphy, Rosemary; Levin, Theodore R.; Watson, Douglas J.; Hwang, Peggy M.T.; Replogle, Amy; Levine, Jeffrey G.

Improving the Reporting of Adverse Drug Reactions: A Cluster-Randomized Trial Among Pharmacists in Portugal
pp. 335-344(10)
Authors: Herdeiro, Maria T.; Polónia, Jorge; Gestal-Otero, Juan J.; Figueiras, Adolfo

Hepatic Events Associated with Atomoxetine Treatment for Attention-Deficit Hyperactivity Disorder
pp. 345-354(10)
Authors: Bangs, Mark E.; Jin, Ling; Zhang, Shuyu; Desaiah, Durisala; Allen, Albert J.; Read, Holly A.; Regev, Arie; Wernicke, Joachim F.

Publishing Histories of Adverse Reactions to Medicaments Anecdotally: The PHARMA guidelines for Reporting Suspected Adverse Drug Reactions
pp. 355-356(2)
Author: Aronson, Jeffrey K.

The Authors' Reply
pp. 356-357(2)
Authors: Kelly, William; Moore, Nicholas; Goldsmith, David I.; Jones, Judith K.; Trenque, Thierry; Eugene van Puijenbroek,